Compare Humana Inc (HUM) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Humana Inc trades at $437.2 (market cap $47.61B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.2 (market cap $1.47B). The key difference: Humana Inc is far larger — about 32.4× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Humana Inc pays a 0.89% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 47 Days on average.
| HUM | QQQE | |
|---|---|---|
Market Cap | $47.61B | $1.47B |
Volume | 1,827,332 | 181,648 |
Sector | Health | Broad Market / Factor |
52-Week High | $409.85 | $124.69 |
52-Week Low | $163.67 | $96.06 |
Typical Hold Time | 53 Days | 47 Days |
Enterprise Value | $54.97B | — |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $121.89, down 0.89% on the day. The ETF maintains a bullish technical outlook with strong moving average signals while oscillators show neutral momentum. Recent analysis highlights QQQE's advantage over traditional NASDAQ-100 ETFs due to its equal-weight approach, reducing technology concentration from 60% to 45% while maintaining exposure to large-cap growth stocks.
The equal-weight methodology provides diversification benefits amid tech sector volatility. Key risks include market concentration in growth stocks and broader market sentiment shifts. Recent analyst commentary suggests tactical opportunities in equal-weight strategies for the coming year, though investors should monitor sector rotation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
